Literature DB >> 24880093

Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.

Antonis Giannakakis1, Athanasios Karapetsas2, Denarda Dangaj3, Evripidis Lanitis3, Janos Tanyi4, George Coukos5, Raphael Sandaltzopoulos6.   

Abstract

T-lymphocyte infiltration in ovarian tumors has been linked to a favorable prognosis, hence, exploring the mechanism of T-cell recruitment in the tumor is warranted. We employed a differential expression analysis to identify genes over-expressed in early stage ovarian cancer samples that contained CD8 infiltrating T-lymphocytes. Among other genes, we discovered that TTF1, a regulator of ribosomal RNA gene expression, and SMARCE1, a factor associated with chromatin remodeling were overexpressed in first stage CD8+ ovarian tumors. TTF1 and SMARCE1 mRNA levels showed a strong correlation with the number of intra-tumoral CD8+ cells in ovarian tumors. Interestingly, forced overexpression of SMARCE1 in SKOV3 ovarian cancer cells resulted in secretion of IL8, MIP1b and RANTES chemokines in the supernatant and triggered chemotaxis of CD8+ lymphocytes in a cell culture assay. The potency of SMARCE1-mediated chemotaxis appeared comparable to that caused by the transfection of the CXCL9 gene, coding for a chemokine known to attract T-cells. Our analysis pinpoints TTF1 and SMARCE1 as genes potentially involved in cancer immunology. Since both TTF1 and SMARCE1 are involved in chromatin remodeling, our results imply an epigenetic regulatory mechanism for T-cell recruitment that invites deciphering.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD8+ T-cell infiltration; CXCL9; Early ovarian cancer; SMARCE1; Termination transcription factor 1

Mesh:

Substances:

Year:  2014        PMID: 24880093     DOI: 10.1016/j.biocel.2014.05.031

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  7 in total

1.  The Potential Tumor Promotional Role of circVAPA in Retinoblastoma via Regulating miR-615-3p and SMARCE1.

Authors:  Qibin Xu
Journal:  Onco Targets Ther       Date:  2020-08-05       Impact factor: 4.147

Review 2.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

Review 3.  Immune Cell Population in Ovarian Tumor Microenvironment.

Authors:  Dong Li Cai; Li-Ping Jin
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

Review 4.  The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.

Authors:  Bo Hu; Jian-Zhen Lin; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Cell Prolif       Date:  2020-03-11       Impact factor: 6.831

5.  A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer.

Authors:  Lu Mao; Yong Tang; Ming-Jing Deng; Chun-Tao Huang; Dong Lan; Wen-Zheng Nong; Li Li; Qi Wang
Journal:  J Clin Lab Anal       Date:  2022-01-07       Impact factor: 2.352

6.  Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Authors:  Athanasios Karapetsas; Antonis Giannakakis; Denarda Dangaj; Evripidis Lanitis; Spyridon Kynigopoulos; Maria Lambropoulou; Janos L Tanyi; Alex Galanis; Stylianos Kakolyris; Gregorios Trypsianis; George Coukos; Raphael Sandaltzopoulos
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

7.  Cigarette smoke and chewing tobacco alter expression of different sets of miRNAs in oral keratinocytes.

Authors:  Mohd Younis Bhat; Jayshree Advani; Pavithra Rajagopalan; Krishna Patel; Vishalakshi Nanjappa; Hitendra S Solanki; Arun H Patil; Firdous A Bhat; Premendu P Mathur; Bipin Nair; T S Keshava Prasad; Joseph A Califano; David Sidransky; Harsha Gowda; Aditi Chatterjee
Journal:  Sci Rep       Date:  2018-05-04       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.